title: Preventative effect of OMZ-SPT on lipopolysaccharide-induced acute lung injury and inflammation via nuclear factor-kappa B signaling in mice.
abstract: Acute lung injury (ALI) is an early pathophysiologic change in acute respiratory distress syndrome and its management can be challenging. Omalizumab (Xolair™) is a recombinant DNA-derived, humanized antibody. OMZ-SPT is a polypeptide on the heavy chain of omalizumab monoclonal antibody. Here, we found that intramuscular administration of OMZ-SPT significantly improved survival and attenuated lung inflammation in female C57BL/6 mice suffering from lipopolysaccharide (LPS)-induced ALI. We also demonstrated that OMZ-SPT can inhibit expression of the inflammatory cytokines tumor necrosis factor-α, interleukin-1β and interleukin-6 by ELISA in mice suffering from LPS-induced ALI and a mouse macrophage line (RAW264.7 cells). In addition, we showed that OMZ-SPT inhibited LPS-induced activation of nuclear factor-kappa B (NF-κB) signaling and total expression of NF-κB by western blotting. These data suggest that OMZ-SPT could be a novel therapeutic choice for ALI.
authors.affiliation: Pediatrics Research Institute, Ministry of Education Key Laboratory of Child Development and Disorders, Children's Hospital of Chongqing Medical University, Chongqing, 400014, China; Department of Respiratory Medicine, Children's Hospital of Chongqing Medical University, Chongqing, 400014, China. Electronic address: wangting2013925@163.com.
authors.forename: Ting
authors.initials: T
authors.lastname: Wang
authors.affiliation: Secular Peptide Biomedicine, Chengdu, China. Electronic address: hwr@cwnu.edu.cn.
authors.forename: Wanru
authors.initials: W
authors.lastname: Hou
authors.affiliation: Pediatrics Research Institute, Ministry of Education Key Laboratory of Child Development and Disorders, Children's Hospital of Chongqing Medical University, Chongqing, 400014, China; Department of Respiratory Medicine, Children's Hospital of Chongqing Medical University, Chongqing, 400014, China. Electronic address: 360412157@qq.com.
authors.forename: Zhou
authors.initials: Z
authors.lastname: Fu
mesh_terms: D055371:Acute Lung Injury / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000737:chemistry / Q000627:therapeutic use*; D005260:Female; D008070:Lipopolysaccharides / Q000276:immunology; D008168:Lung / Q000187:drug effects* / Q000276:immunology / Q000473:pathology; D008810:Mice, Inbred C57BL; D016328:NF-kappa B / Q000276:immunology*; D000069444:Omalizumab / Q000737:chemistry / Q000627:therapeutic use*; D010455:Peptides / Q000737:chemistry / Q000627:therapeutic use; D011014:Pneumonia / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D000893:Anti-Inflammatory Agents; D008070:Lipopolysaccharides; D016328:NF-kappa B; D010455:Peptides; D000069444:Omalizumab
keywords: Acute lung injury; Inflammation; NF-κB; OMZ-SPT